July 11, 2022: “Bayer announced that new data from the company’s growing radiology portfolio will be presented at the 2022 European Congress of Radiology (ECR), taking place from July 13 to 17 in Vienna, Austria.
The presentations reinforce Bayer’s position as a leading company in key radiology areas and its commitment to accelerate innovation for the ultimate benefit of patients and their physicians, including leveraging the vast potential of artificial intelligence (AI).
The presentations highlight preclinical data on the novel development compound gadoquatrane, which is currently in Phase II development.
Gadoquatrane features high stability as well as high relaxivity, which is a key property for use in contrast-enhanced magnetic resonance imaging (MRI), with the potential to enable a substantially lower gadolinium (Gd) dose.
Another focus is on clinical data on Bayer’s MRI contrast agent Gadovist™ (gadobutrol), investigating the clinical efficacy of a reduced dose of gadobutrol compared to a standard dose of gadoterate in patients undergoing a steady-state contrast-enhanced MRI of the central nervous system (CNS).
Artificial intelligence is currently one of the most-discussed topics in radiology and will be one of the highlights of the ECR again this year. Bayer is committed to further driving advances in AI.
At this year’s ECR, one early research presentation by Bayer explores the potential of deep learning to achieve optimized contrast media administration utilizing a generative adversarial network.
AI can help manage the mounting workload of radiologists and their teams, ultimately striving to improve patient care.
Bayer recently announced the launch of Calantic™ Digital Solutions, a new platform delivering access to digital applications, including artificial intelligence enabled programs, for medical imaging.
The offering contains tools which aid radiologists and their teams to improve prioritization, lesion detection, quantification and productivity.
By providing access to AI radiology applications through the Calantic Digital Solutions platform Bayer will expand its comprehensive portfolio beyond contrast media, medical devices, software and services.
The new platform will support healthcare professionals at all stages of their work from diagnosis through treatment of their patients.
First launch markets will include the US and several European countries, with more regions to follow, each upon local regulatory approvals as applicable.”
